Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company based in San Diego, California, focusing on transforming care in Asthma and Chronic Obstructive Pulmonary Disease (COPD) [3] - The company is advancing Rademikibart™, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which aims to address acute indications in asthma and COPD [3] Upcoming Conferences - Company management will participate in the Leerink Partners Global Biopharma Conference on March 12, 2025, at 1:40 p.m. ET [1] - The company will also be present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 2:30 p.m. ET [2] - Live webcasts for these events will be available on Connect's website, with archived replays accessible for approximately 90 days post-event [2] Market Opportunity - Rademikibart targets approximately 1 million asthma and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually, representing a significant untapped market [3] - The drug has shown promising efficacy and safety in Phase 2 studies, with a rapid onset of action observed as early as 24 hours [3]
Connect Biopharma to Present at Two Upcoming Investor Conferences